Ablation

Global Radiofrequency Ablation Devices Market to Grow Alongside Technological Maturity of the Healthcare Sector, TMR

Monday, June 1, 2020 - 12:36pm

These investments flow in from state authorities and angel investors

Key Points: 
  • These investments flow in from state authorities and angel investors
    ALBANY, New York, June 1, 2020 /PRNewswire/ -- The presence of a growth-oriented healthcare sector has created fresh opportunities for growth within the global radiofrequency ablation devices market.
  • It is expected that the global radiofrequency ablation devices market would fetch formidable revenues from key stakeholders and healthcare investors.
  • Probes and electrodes are known reusable devices that correspond to the radiofrequency ablation devices market.
  • Besides, the proven efficiency of radiofrequency ablation devices has also brought them under the radar of focus/ Over the course of the next decade, the total volume of revenues within the global radiofrequency ablation devices market shall touch new heights.

Boston Scientific Launches DIRECTSENSE™ Technology

Monday, June 1, 2020 - 11:50am

MARLBOROUGH, Mass., June 1, 2020 /PRNewswire/ --Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation procedures.

Key Points: 
  • MARLBOROUGH, Mass., June 1, 2020 /PRNewswire/ --Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation procedures.
  • The DIRECTSENSE Technology provides data on the impedance around the catheter tip to measure the ability of the tissue to respond to RF energy before physicians deliver therapy.
  • "Building upon the success seen with the DIRECTSENSE Technology in Europe, we are pleased to introduce this tool to physicians and their patients in the U.S.," said Kenneth Stein, M.D., senior vice president and chief medical officer, Rhythm Management and Global Health Policy, Boston Scientific.
  • Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.

The Asia Pacific radiofrequency ablation devices market is anticipated to reach US$ 1,705.06 Mn by 2027 from US$ 699.62 Mn in 2019. The market is projected to grow at a CAGR of 12.1% from 2020 to 2027

Saturday, May 23, 2020 - 1:15am

The Asia Pacific radiofrequency ablation devices market is anticipated to reach US$ 1,705.06 Mn by 2027 from US$ 699.62 Mn in 2019.

Key Points: 
  • The Asia Pacific radiofrequency ablation devices market is anticipated to reach US$ 1,705.06 Mn by 2027 from US$ 699.62 Mn in 2019.
  • The market is projected to grow at a CAGR of 12.1% from 2020 to 2027.
  • The radiofrequency ablation devices market growth is primarily attributed to the rising prevalence of chronic diseases, emerging applications of radiofrequency ablation technology, and increasing preference for minimally invasive procedures in Asia Pacific.
  • In 2019, the surgical oncology segment held the largest share of the Asia Pacific radiofrequency ablation devices market, by application, in 2019.

CLS Conducts In-Vivo Laser Ablation Studies for Neuro and Prostate using TRANBERG Thermal Therapy System with Thermoguide

Friday, May 22, 2020 - 9:00am

IRVINE, Calif. and LUND, Sweden, May 22, 2020 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS) today announced it is conducting new in-vivo precision laser ablation treatment studies for neuro and prostate using its TRANBERG Thermal Therapy System with Thermoguide thermometry software.

Key Points: 
  • IRVINE, Calif. and LUND, Sweden, May 22, 2020 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS) today announced it is conducting new in-vivo precision laser ablation treatment studies for neuro and prostate using its TRANBERG Thermal Therapy System with Thermoguide thermometry software.
  • This quarter, CLS will initiate preclinical studies in neuro and prostate scheduled to last throughout the year.
  • We will continue to market and sell our existing products while finalizing the application for the new TRANBERG Thermal Therapy System with Thermoguide Workstation, says Dan Mogren, Chief Commercial Officer at CLS.
  • The TRANBERG Thermal Therapy System includes a small, user-friendly mobile laser unit with unique monitoring capabilities and tailored single-use products specifically developed to enable safe, efficient, precision laser ablation procedures using all types of image guidance.

Thermedical’s Groundbreaking SERF Ablation System Earns FDA’s Breakthrough Device Designation

Tuesday, May 19, 2020 - 2:00pm

Thermedical , a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), today announced that it has received Breakthrough Device Designation from the U.S. Food & Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter.

Key Points: 
  • Thermedical , a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), today announced that it has received Breakthrough Device Designation from the U.S. Food & Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter.
  • View the full release here: https://www.businesswire.com/news/home/20200519005159/en/
    Thermedical's Durablate catheter receives Breakthrough Device Designation from the U.S. Food & Drug Administration.
  • Thermedicals SERF ablation system provides a new form of biological heat transfer that is 20 times more effective at transferring heat than conventional ablation methods.
  • The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Durablate catheter to treat VT.

Thermedical Announces SERF VT Study Presented as Part of HRS 2020 Science Late-Breaking Clinical Trial Sessions

Friday, May 8, 2020 - 1:05pm

Thermedical , a developer of thermal-ablation systems to treat ventricular tachycardia (VT), announced that results from a First-in-Human Early Feasibility Study (EFS) using the new Durablate catheter to treat VT were presented in the late-breaking clinical trial sessions at the Heart Rhythm Society (HRS) meeting today.

Key Points: 
  • Thermedical , a developer of thermal-ablation systems to treat ventricular tachycardia (VT), announced that results from a First-in-Human Early Feasibility Study (EFS) using the new Durablate catheter to treat VT were presented in the late-breaking clinical trial sessions at the Heart Rhythm Society (HRS) meeting today.
  • The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Durablate catheter to treat VT , a leading cause of sudden cardiac death worldwide.
  • The target study population consists of patients who have failed all current forms of treatment including Implantable Cardioverter Defibrillators (ICDs), medical therapy and other forms of ablation therapy.
  • The Early Feasibility Study is the first human use of the Durablate Catheter Ablation System in the U.S. and Canada.

CLS Granted New U.S. Patent Covering Unique, Non-Cooled, Diffuser-type Laser Ablation Applicator

Wednesday, April 29, 2020 - 12:00pm

IRVINE, Calif. and LUND, Sweden, April 29, 2020 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS) today announced it was granted a new U.S. Patent valid until 2036 covering its unique, non-cooled, diffuser-type laser ablation applicator.

Key Points: 
  • IRVINE, Calif. and LUND, Sweden, April 29, 2020 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS) today announced it was granted a new U.S. Patent valid until 2036 covering its unique, non-cooled, diffuser-type laser ablation applicator.
  • CLSs diffuser-type laser ablation applicator enables the treatment of larger cancer tumors and is part of the company's extensive portfolio of laser applicators and instruments that, together with CLS's mobile laser unit, constitute the TRANBERG Thermal Therapy System .
  • This patent represents the latest milestone in our continuing technology development of high-precision, MRI-guided thermal therapy products and accessories, stated Dan Mogren, Chief Commercial Officer for CLS.
  • Our image-guided system and instruments enable high precision, minimally invasive laser ablation treatments for challenging indications, such as prostate cancer.

The Global Tumor Ablation Market is expected to grow from USD 473.95 Million in 2018 to USD 1,649.04 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 19.49%

Tuesday, April 28, 2020 - 11:20pm

On the basis of Treatment, the Global Tumor Ablation Market is studied across Laparoscopic Ablation, Percutaneous Ablation, and Surgical Ablation.

Key Points: 
  • On the basis of Treatment, the Global Tumor Ablation Market is studied across Laparoscopic Ablation, Percutaneous Ablation, and Surgical Ablation.
  • On the basis of Application, the Global Tumor Ablation Market is studied across Bone Metastasis, Kidney Cancer, Liver Cancer, and Lung Cancer.
  • What are the factors that affect the growth in the Global Tumor Ablation Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Tumor Ablation Market?

The Global Tissue Ablation Market is expected to grow from USD 13,823.13 Million in 2018 to USD 22,452.13 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.17%

Wednesday, April 15, 2020 - 9:00am

On the basis of Type, the Global Tissue Ablation Market is studied across Cardiology, Cosmetology, Gynecology, Oncology, Ophthalmology, and Urology.

Key Points: 
  • On the basis of Type, the Global Tissue Ablation Market is studied across Cardiology, Cosmetology, Gynecology, Oncology, Ophthalmology, and Urology.
  • On the basis of Application, the Global Tissue Ablation Market is studied across Cryoablation Devices, EBRT, Hydrothermal Ablation, Laser-Based Ablation, Microwave Ablation, Radiofrequency Ablation, and Ultrasound Ablation.
  • What are the factors that affect the growth in the Global Tissue Ablation Market over the forecast period?
  • Which are the best product areas to be invested in over the forecast period in the Global Tissue Ablation Market?

GIGAPHOTON Launches 300W KrF Laser “G300K” for Micro Ablation Via Processing

Tuesday, April 14, 2020 - 1:00am

The KrF laser G300K is based on Gigaphotons KrF laser technology for lithography light sources, and under the concept of optimizing processing of micro ablation and so on, it is a model that is affordable while maintaining high stability, a high availability of 99% or more, and a high output.

Key Points: 
  • The KrF laser G300K is based on Gigaphotons KrF laser technology for lithography light sources, and under the concept of optimizing processing of micro ablation and so on, it is a model that is affordable while maintaining high stability, a high availability of 99% or more, and a high output.
  • This supports productivity improvements and cost reduction in the micro ablation via processing process in semiconductor manufacturing back-end processes.
  • Micro-ablation via processing of organic insulating films has drawn much attention because it can be performed at high speed and at low cost.
  • Since it was founded in 2000, GIGAPHOTON has delivered valuable solutions to semiconductor manufacturers throughout the world as a laser supplier.